Correlation of mast cells with clinical characteristics
| Factor . | No. . | Median . | Range . | P . |
|---|---|---|---|---|
| Total no. of mast cells | 56 | 59 | 3-142 | |
| Sex | NS | |||
| Male | 28 | 55.5 | 15-142 | |
| Female | 28 | 60 | 3-118 | |
| Age, y | NS | |||
| <18 | 4 | 40.5 | 3-100 | |
| ≥18 | 52 | 59.5 | 13-142 | |
| Donor type | NS | |||
| Matched sibling/haploidentical | 20/1 | 59 | 13-142 | |
| Matched unrelated donor | 4 | 66 | 26-100 | |
| Single-unit umbilical cord blood | 8 | 51 | 23-126 | |
| Double-unit umbilical cord blood | 23 | 60 | 3-118 | |
| Diagnosis | NS | |||
| AA | 1 | 26 | ||
| ALL/AML/MDS/MPN | 39 | 60 | 3-142 | |
| CML | 2 | 55 | 51-59 | |
| NHL/HL | 8 | 53.5 | 25-78 | |
| MM | 6 | 75.5 | 47-126 | |
| Disease risk index | NS | |||
| Low | 11 | 50 | 3-78 | |
| Intermediate | 34 | 67.5 | 13-142 | |
| High/very high | 10 | 58 | 32-91 | |
| Nonmalignant | 1 | 26 | ||
| Conditioning | <.01* | |||
| MAC | 29 | 47 | 3-100 | |
| RIC | 27 | 78 | 32-142 | |
| GVHD prophylaxis | NS | |||
| Cyclosporine A/methotrexate | 10 | 59 | 25-100 | |
| Cyclosporine A/mycophenolate mofetil | 35 | 59 | 3-142 | |
| Sirolimus/mycophenolate mofetil | 7 | 60 | 32-126 | |
| Other | 4 | 50 | 23-91 | |
| Karnofsky score | NS | |||
| ≤80 | 11 | 50 | 23-129 | |
| >80 | 45 | 59 | 3-142 | |
| HCT-specific comorbidity index | NS | |||
| Low risk | 16 | 46.5 | 3-126 | |
| Intermediate risk | 19 | 67 | 13-142 | |
| High risk | 20 | 59.5 | 26-118 | |
| Missing | 1 | — |
| Factor . | No. . | Median . | Range . | P . |
|---|---|---|---|---|
| Total no. of mast cells | 56 | 59 | 3-142 | |
| Sex | NS | |||
| Male | 28 | 55.5 | 15-142 | |
| Female | 28 | 60 | 3-118 | |
| Age, y | NS | |||
| <18 | 4 | 40.5 | 3-100 | |
| ≥18 | 52 | 59.5 | 13-142 | |
| Donor type | NS | |||
| Matched sibling/haploidentical | 20/1 | 59 | 13-142 | |
| Matched unrelated donor | 4 | 66 | 26-100 | |
| Single-unit umbilical cord blood | 8 | 51 | 23-126 | |
| Double-unit umbilical cord blood | 23 | 60 | 3-118 | |
| Diagnosis | NS | |||
| AA | 1 | 26 | ||
| ALL/AML/MDS/MPN | 39 | 60 | 3-142 | |
| CML | 2 | 55 | 51-59 | |
| NHL/HL | 8 | 53.5 | 25-78 | |
| MM | 6 | 75.5 | 47-126 | |
| Disease risk index | NS | |||
| Low | 11 | 50 | 3-78 | |
| Intermediate | 34 | 67.5 | 13-142 | |
| High/very high | 10 | 58 | 32-91 | |
| Nonmalignant | 1 | 26 | ||
| Conditioning | <.01* | |||
| MAC | 29 | 47 | 3-100 | |
| RIC | 27 | 78 | 32-142 | |
| GVHD prophylaxis | NS | |||
| Cyclosporine A/methotrexate | 10 | 59 | 25-100 | |
| Cyclosporine A/mycophenolate mofetil | 35 | 59 | 3-142 | |
| Sirolimus/mycophenolate mofetil | 7 | 60 | 32-126 | |
| Other | 4 | 50 | 23-91 | |
| Karnofsky score | NS | |||
| ≤80 | 11 | 50 | 23-129 | |
| >80 | 45 | 59 | 3-142 | |
| HCT-specific comorbidity index | NS | |||
| Low risk | 16 | 46.5 | 3-126 | |
| Intermediate risk | 19 | 67 | 13-142 | |
| High risk | 20 | 59.5 | 26-118 | |
| Missing | 1 | — |
NS, not significant.
False discovery rate, 0.02.